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Neuropeptide Y (NPY) regulation of intracellular cyclic AMP accumulation was studied in human E~ving's arcoma cell 
line, WE-68. NPY inhibited vasoactive intestinal peptide (VIP)- and dopamine-stimulated but not basal cyclic AMP for- 
mation. The peptide effect was rapid (< 2 rain), concentration-dependent with a half-maximal effective concentration 
(ECso) of 8 nM NPY, and maximal inhibition reaching 60-70% with 100 nM NPY. Prior exposure of WE-68 cells to 
pertussis toxin completely abolished the inhibitory action of NPY. It is concluded that NPY attenuates agonist-stimulated 
cyclic AMP formation in Ewing's sarcoma WE-68 cells, and may do so via the inhibitory guanine nucleotide regulatory 
protein of adenylate cyclase. 
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1. INTRODUCTION 
Neuropeptide Y (NPY) is a 36-amino-acid 
polypeptide and was originally isolated from por- 
cine brain [1]. NPY is localized in both central and 
peripheral neurons, and evidence is accumulating 
that the peptide acts as a neurotransmitter or 
neuromodulator controlling various physiological 
events [2]. Specific recognition sites for NPY have 
been identified in rat cerebral cortex [3] and rat 
phaeochromocytoma cells [4]. With regard to 
transmembrane signalling systems, NPY has been 
shown to inhibit cyclic AMP production in the 
nucleus tractus olitarius region of rat brain [5] and 
human neuroblastoma cells [6]. 
Ewing's sarcoma is the second most frequent 
childhood tumor of bone and was first described in 
1921 [7]. Few data are available as yet concerning 
the regulatory role of hormones or other factors on 
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second messenger systems in Ewing's sarcoma 
cells. WE-68 is a recently established human Ew- 
ing's sarcoma cell line which displays neural 
features, namely neurofilaments, S-100 protein, 
Leu-7 antigen and neuron-specific enolase [8]. In 
addition, the WE-68 cyclic AMP-generating system 
responds to classical neurotransmitters such as fl- 
adrenergic and dopaminergic agonists [9,10] as 
well as the neuropeptide vasoactive intestinal pep- 
tide (VIP) [11]. Based on these findings it was op- 
portune to study the effects of the neuropeptide 
NPY, both alone and in combination with VIP and 
dopamine, upon cyclic AMP production in the 
WE-68 cell line. Our data provide the first evidence 
for dual regulation of cyclic AMP metabolism by 
neuroactive ligands in Ewing's sarcoma cells. 
2. MATERIALS AND METHODS 
Synthetic human NPY and human VIP were obtained from 
Peninsula (St. Helens, England) and dopamine, pertussis 
toxin and 3-isobutyl-l-methylxanthine (IBMX) from Sigma 
(Miinchen). 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/89/$3.50 © 1989 Federation of European Biochemical Societies 271 
Volume 249, number  2 FEBS LETTERS June 1989 
2.0 -  
F 
o 
~ 1.5 -  
c 
1.0 -  
; 
< 
o 
~0.5 -  
Ib-IP 
, ,  I I I 
-8  -7 -6  -5  
V IP  (M) 
I /d  I , I 
0 -8  -7 -6  -5  -4  
OOPAMINE (M) 
Fig.1. Cyclic AMP formation in human Ewing's sarcoma 
WE-68 cells incubated with increasing concentrations of VIP 
(O,O) or dopamine (D, - )  in the absence (open symbols) and 
presence (closed symbols) of 1 #M NPY. Values are 
means _+ SE of triplicate determinations on four separate 
culture preparations. 
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Fig.2. Time course of cyclic AMP formation in human Ewing's 
sarcoma WE-68 cells incubated in the absence (O,o) or 
presence (Q ,m, , )  of 1/zM VIP without (open symbols) and 
with (closed symbols) 200 nM NPY added either at 0 rain (e , - )  
or after 5 rain (A) of incubation. Values are means ± SE of 
triplicate determinations on four separate culture preparations. 
Ewing's sarcoma WE-68 cells were maintained inFalcon T-75 
flasks in Dulbecco's modified Eagle's medium/Ham's for- 
mula-12 (I : 1; DME/F12) supplemented with 5070 FCS [10]. For 
cyclic AMP studies, cells were propagated into 24-well Costar 
plates. Confluent cultures were incubated with pertussis toxin or 
vehicle (PBS, pH 7.4) for 18 h at the indicated concentrations i  
DME/FI2 supplemented with 0.5070 FCS before testing cyclic 
AMP response to agonists. 
The procedure for incubating the cells in order to study cyclic 
AMP accumulation has been described [9]. Briefly, cells were 
preincubated for 15 min in 180/d Hanks' buffered with 20 mM 
Hepes (HH, pH 7.4) containing 1mM IBMX. Thereafter, 20/~1 
agonist solution was added and cells incubated for an additional 
15 rain unless otherwise indicated. Incubations were stopped by 
adding 20/zl of 55070 (w/v) trichloroacetic acid to each well. 
After neutralization f the incubation mixture with 80/d of 1 M 
Tris, total cell and medium cyclic AMP was determined by 
radioimmunoassay [10]. Cell protein was measured by the Bio- 
Rad protein assay (Bio-Rad, Miinchen) using human serum 
albumin as standard. 
Data shown represent means ± SE of four experiments each 
performed in triplicate. 
3. RESULTS 
As  demonst ra ted  in fig. 1, 1/~M NPY at tenuated  
the  concent ra t ion -dependent  s t imu la tory  ef fect  o f  
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Fig.3. Cyclic AMP formation in human Ewing's sarcoma 
WE-68 cells incubated with increasing concentrations of NPY in 
• the absence (O) and presence of either 2/~M VIP (o) or 10/~M 
dopamine (e). Values are means + SE of triplicate determina- 
tions on four separate culture preparations. 
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VIP on cyclic AMP generation in human Ewing's 
sarcoma WE-68 cells. In the presence of NPY, 
maximal cyclic AMP response to VIP (3/zM) was 
suppressed by 70%. The ECso for VIP stimulation 
was 0.2/~M in both the absence and presence of the 
inhibitory peptide. A similar pattern was observed 
with the action of NPY on the cyclic AMP response 
to dopamine (fig. 1). The ECso for dopamine leva- 
tion of cyclic AMP was 0.3/zM and remained un- 
changed in the presence of 1/zM NPY whereas this 
concentration f the inhibitory peptide caused 60% 
reduction in the 10/zM dopamine-stimulated cyclic 
AMP accumulation. NPY (200 nM), added either 
simultaneously with VIP or after 5 min of incuba- 
tion with VIP, caused inhibition of cyclic AMP 
formation after as little as 2 min incubation (fig.2). 
NPY was without effect on basal cyclic AMP levels 
over the entire time course studied. NPY inhibited 
both VIP (2/zM)- and dopamine (10/~M)-induced 
cyclic AMP formation (fig.3) with an ECso of 8 nM 
NPY and maximal inhibition for 100 nM. Basal 
cyclic AMP levels in WE-68 cells were not influenc- 
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Fig.4. Cyclic AMP formation in human Ewing's sarcoma 
WE-68 cells pretreated for 18 h with increasing concentrations 
of pertussis toxin and then exposed toeither 1/zM VIP (O,e) or 
0.5 /~M dopamine (ra,m) without (open symbols) and with 
(closed symbols) 100 nM NPY. Values are means + SE of 
triplicate determinations  four separate culture preparations. 
ed by NPY in the concentration range 1 nM-1/zM. 
The mechanism of NPY action was evaluated by 
using pertussis toxin as a probe for the inhibitory 
pathway of cyclic AMP formation [12]. Pertussis 
toxin treatment of WE-68 cells abolished the in- 
hibitory effect of NPY on VIP- and dopamine- 
stimulated cyclic AMP accumulation (rigA) with 
an ECso of 2 ng/ml of the toxin. The stimulatory 
action of both VIP and dopamine was unaffected 
by pertussis toxin at up to 1/zg/ml. 
4. DISCUSSION 
Our data clearly show that NPY is a potent in- 
hibitor of cyclic AMP accumulation i human Ew- 
ing's sarcoma WE-68 cells. NPY does not affect 
basal cyclic AMP levels whereas the neuropeptide 
attenuates the increase in cyclic AMP formation 
due to the stimulatory effects of VIP and dopa- 
mine. A permissive role upon the NPY inhibitory 
cyclic AMP response has been reported for VIP 
and isoproterenol [6] and the adenylate cyclase ac- 
tivator forskolin [5,13,14] with other intact cells 
and tissues. NPY decreases maximal stimulation of 
cyclic AMP formation by both VIP and dopamine 
without changing their potencies, suggesting an in- 
teraction of NPY with its own receptors in WE-68 
cells. Furthermore, the demonstration of the NPY 
effect in the presence of the phosphodiesterase in- 
hibitor IBMX indicates that NPY acts through 
direct inhibition of adenylate cyclase and not via 
increased cyclic AMP degradation. In this regard, 
NPY has been shown to inhibit adenylate cyclase 
activity in human cerebral cortex [15], rat hippo- 
campus [16] and a cell line from a human neuro- 
blastoma [6]. Our data obtained with pertussis tox- 
in suggest hat NPY receptor inhibition may be 
mediated by Ni, the inhibitory guanine nucleotide 
regulatory protein of adenylate cyclase. It is now 
well accepted that the stimulation and inhibition of 
adenylate cyclase appear to be mediated by the 
distinct guanine nucleotide regulatory proteins Ns 
and Ni, respectively [17]. A common/?-subunit ap- 
pears to be the link and, therefore, the effector of 
the equilibrium between the two systems [18]. Per- 
tussis toxin selectively ADP-ribosylates and inacti- 
vates Ni [19]. 
In conclusion, the present results in the WE-68 
human Ewing's sarcoma cell line suggest he ex- 
istence of NPY receptors coupled to adenylate 
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cyclase in an inhibitory manner,  probably through 
Ni. 
F rom a histological point of view, our data 
represent addit ional support o the concept of the 
expression of neural characteristics in the Ewing's 
bone tumor cell line, WE-68 [8,11]. 
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